Acute myeloid leukemia: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• FLT3 36
• TP53 9
• NPM1 26
• IDH 29
• KMT2A 20
• RUNX1 2
• CD123 19
• BCL-2 10
• ABL1 2
• CD33 17
• PI3K 3
• mTOR 0
• KIT 3
• JAK 1
• CD19 8
• MAPK 0
• STAT3 0
• ERK 0
• AKT 0
• CD38 6
• HDAC 2
• MYC 1
• PD-1 4
• PPAR 0
• CXCR4 0
• NRF2 0
• BRD4 0
• PD-L1 0
• RAS 0
• STING 1
• HIF-1 0
• TIM-3 0
• METTL3 0
• CD47 1
• CTNNB1 0
• JNK 0
• KRAS 0
• MEK 0
• PARP 3
• EZH2 0
• IL-6 2
• BRAF 0
• EGFR 0
• FTO 0
• HSP90 0
• PDGFR 0
• PTEN 0
• CDK4/6 0
• FGFR 2
• GPX4 0
• HMGB1 0
• NLRP3 0
• NRAS 0
• SHP2 0
• AMPK 0
• CD20 1
• IL-15 1
• MDM2 0
• PINK1 0
• PKM2 0

EU-13 is a filter, not a ranking: it only narrows the list.

4 of 4+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Trials whose registry record says individual participant data (IPD) will be shared.

• Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation

  NCT03953898· National Cancer Institute (NCI)· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 39
• Mendelian Randomization Analysis 3
• CRISPR-Cas Systems 16
• Gene Expression Profiling 84
• Sequence Analysis, RNA 6
• Whole Genome Sequencing 7
• Exome Sequencing 1
• Proteomics 28
• Metabolomics 10
• Mass Spectrometry 3
• Flow Cytometry 86
• Immunohistochemistry 14
• Liquid Biopsy 1
• Circulating Tumor DNA 3
• Xenograft Model Antitumor Assays 159
• Positron-Emission Tomography 1
• Magnetic Resonance Imaging 11
• Machine Learning 33
• Deep Learning 12
• Cohort Studies 30
• Genome-Wide Association Study 3

• An integrated deep learning and molecular dynamics pipeline for the discovery of novel CDK8 inhibitors against acute myeloid leukaemia.

  SAR QSAR Environ Res, Aug 2026

• The role of computational pathology in predicting expression of selected immunohistochemical markers.

  Pol J Pathol, Jun 2026

• Detection of acute lymphocytic and myeloid leukaemia with optimized dimensionality reduction and deep learning classification framework.

  Curr Res Transl Med, Jun 2026

• Optimizing Deep Learning for Renal Mass Characterization in Challenging Cases: A Comparative Study of Spatial-Input Strategies and a Validated ROI-Only DLR Nomogram.

  Ann Surg Oncol, May 2026

• Adaptive multimodal learning for driver cognitive state monitoring using transformer-based fusion with personalized meta-learning and federated optimization.

  Sci Rep, May 2026

• Improving severity grading of chemotherapy-induced myelosuppression in AML via data-driven and model-based deep learning.

  NPJ Syst Biol Appl, Mar 2026

• A meta learning and task adaptive approach for drug target affinity prediction.

  Nat Commun, Mar 2026

• A deep learning ensemble framework for multi-subtype renal tumor classification using contrast-enhanced CT.

  Sci Rep, Jan 2026

• ProTCR: a protein language model-driven framework for decoding TCR-antigen recognition toward precision immunotherapies.

  Brief Bioinform, Jan 2026

• Deep learning in bone marrow cytomorphology: advances in segmentation, classification, and clinical translation.

  Med Oncol, Nov 2025

See which targets of this disease your abstract mentions, and go to the people working on them.